Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional data
11:43am, Wednesday, 12'th Nov 2025
Novo Nordisk released new data to underscore its pill's safety and effectiveness, while Trump is asked whether private plans could see lower GLP-1 costs.
Novo Nordisk Cuts Wegovy Price in India as Eli Lilly's Mounjaro Leads Market
11:18am, Wednesday, 12'th Nov 2025
Novo Nordisk (NVO, Financials) has lowered the price of its obesity drug Wegovy in India by as much as 37%, as it looks to catch up with Eli Lilly's fast-sellin
Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3?
09:36am, Wednesday, 12'th Nov 2025
Novo Nordisk eyes a 2026 comeback as it slashes jobs, cuts U.S. semaglutide prices and focuses on expanding the reach of key drugs after a weak Q3.
Novo Resources Announces Updated Investor Presentation
11:32pm, Tuesday, 11'th Nov 2025
PERTH, Australia, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce that it has released an updated corporate pr
Novo Nordisk: Consider The Counterfactual
12:35pm, Tuesday, 11'th Nov 2025
The Novo Nordisk stock has really been through it this year, reaching a third of its level seen during the highs of mid-2024. The company's softening sales performance, which prompted restructuring, h
Virtus SGA International Growth Q3 2025 Portfolio Activity
11:55am, Tuesday, 11'th Nov 2025
At the beginning of the quarter, Virtus liquidated its position in Novo Nordisk (NVO) and used the proceeds to fund a new position in Japanese retail holding company, Fast Retailing (FRCOY). We also i
Top Analysts See S&P 500 Climbing 7,500 by 2026 on AI Momentum
11:10am, Tuesday, 11'th Nov 2025
UBS raised its year-end view for the S&P 500, saying the index could reach 7,500 in 2026, driven by AI-led earnings growth and strong technology spending, accor
GLP-1 prices are dropping: Who exactly will benefit?
10:25am, Tuesday, 11'th Nov 2025
CNBC's Bertha Coombs asks President Trump and his team at the White House's announcement on lower prices for Eli Lilly and Novo Nordisk's GLP-1 medications, if those new prices will extend to commerci
3 Buy-And-Forget Dividend Stocks With Snowballing Payouts
10:07am, Tuesday, 11'th Nov 2025
If the headline yield today is not something you're concerned with, and you pay more attention to how fast a yield can grow, then it's worth buying dividend stocks you can forget about for decades.
Why Novo Nordisk slashed prices of its weight-loss drug in India: 5 key points
09:52am, Tuesday, 11'th Nov 2025
Novo Nordisk has cut the price of its blockbuster weight-loss drug Wegovy by up to 33% in India, a Reuters report said on Tuesday. The move aimed at expanding access and defending market share amid fi
Exclusive: Novo Nordisk cuts Wegovy price by up to 33% in India, document shows
08:42am, Tuesday, 11'th Nov 2025
Danish drugmaker Novo Nordisk on Tuesday cut the price of its blockbuster weight-loss drug, Wegovy, by up to 33% in India, according to a document seen by Reuters.
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
04:25am, Tuesday, 11'th Nov 2025
Eli Lilly's GLP-1 drug is now the world's best-selling drug. Novo Nordisk is struggling with declining market share.
Novo Nordisk: Buy This Bargain
05:28pm, Monday, 10'th Nov 2025
Novo Nordisk A/S shares have declined sharply, but the company remains profitable with a positive long-term growth outlook and a strong cash position. NVO's decision to walk away from the Metsera, Inc
Pfizer to acquire Metsera after winning bidding contest against Novo Nordisk
11:53am, Monday, 10'th Nov 2025
Metsera (NASDAQ:MTSR) announced that it has entered into an amended merger agreement with Pfizer Inc (NYSE:PFE, ETR:PFE), under which Pfizer will acquire the biotech company for up to $86.25 per shar
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
11:31am, Monday, 10'th Nov 2025
NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.
